Jeanette Hoffman, Executive Director for Patients Come First New Jersey, expressed concerns that government-imposed price controls on prescription drugs could inadvertently hinder biopharmaceutical innovation. This statement was made in a letter to the editor.
“Unfortunately, recent efforts to implement government price controls on prescription drugs, while well-intentioned, could have the unintended consequence of stalling biopharmaceutical innovation, and as a result, a cure for Alzheimer’s,” said Hoffman. “When companies are unable to recover the massive costs associated with developing new drugs—often over a decade and billions of dollars—they are forced to scale back or even abandon promising scientific research.”
The 340B Drug Pricing Program, established in 1992, enables eligible healthcare providers to purchase outpatient drugs at reduced prices to better serve low-income and uninsured patients. Recent studies have highlighted concerns that these savings are not consistently directed towards patient care. The program’s increasing complexity has underscored the need for enhanced transparency and reform.
According to a 2024 study, the number of 340B contract pharmacy arrangements expanded significantly from 1,300 in 2010 to over 60,000 by 2022. However, there is limited evidence indicating that patients directly benefit from these savings. Researchers emphasized the importance of transparency to ensure that the financial benefits of the program reach the intended populations.
PhRMA reports that 25 hospitals in New Jersey participate in the 340B program, maintaining 547 contracts with pharmacies nationwide. Of these contract pharmacies, only 18% are situated in medically underserved areas. Additionally, only 16% of participating hospitals in New Jersey provide charity care at levels below the national average.
Hoffman leads Patients Come First New Jersey, a patient advocacy group committed to prioritizing patient interests within healthcare policy. The organization advocates for transparency, access, and innovation for patients across the state and strives to ensure that patient voices are represented in critical health policy discussions.
